BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 17515522)

  • 1. Measuring HRQOL in patients with cutaneous T-cell lymphoma undergoing therapy with oral bexarotene and extracorporeal photopheresis.
    Demierre MF; Ferzli P; Miller D
    Arch Dermatol; 2007 May; 143(5):659-61. PubMed ID: 17515522
    [No Abstract]   [Full Text] [Related]  

  • 2. Open-label pilot study of combination therapy with rosiglitazone and bexarotene in the treatment of cutaneous T-cell lymphoma.
    Sepmeyer JA; Greer JP; Koyama T; Zic JA
    J Am Acad Dermatol; 2007 Apr; 56(4):584-7. PubMed ID: 17184879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regression of multifocal, skin-restricted, CD30-positive large T-cell lymphoma with interferon alfa and bexarotene therapy.
    French LE; Shapiro M; Junkins-Hopkins JM; Vittorio CC; Rook AH
    J Am Acad Dermatol; 2001 Dec; 45(6):914-8. PubMed ID: 11712039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of cutaneous T-Cell lymphoma patients with extracorporeal photopheresis. The Hellenic experience.
    Siakantaris MP; Tsirigotis P; Stavroyianni N; Argyropoulos KV; Girkas K; Pappa V; Chondropoulos S; Papadavid E; Sakellari I; Anagnostopoulos A; Antoniou C; Dervenoulas J
    Transfus Apher Sci; 2012 Apr; 46(2):189-93. PubMed ID: 22178592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A case of poikiloderma vasculare atrophicans, a rare variant of cutaneous T-cell lymphoma, responding to extracorporeal photopheresis.
    Kreuter A; Hoffmamm K; Altmeyer P
    J Am Acad Dermatol; 2005 Apr; 52(4):706-8. PubMed ID: 15793532
    [No Abstract]   [Full Text] [Related]  

  • 6. Extracorporeal photopheresis and multimodality immunomodulatory therapy in the treatment of cutaneous T-cell lymphoma.
    Richardson SK; McGinnis KS; Shapiro M; Lehrer MS; Kim EJ; Vittorio CC; Junkins Hopkins JM; Rook AH
    J Cutan Med Surg; 2003; 7(4 Suppl):8-12. PubMed ID: 12958701
    [No Abstract]   [Full Text] [Related]  

  • 7. Bexarotene: new preparation. Cutaneous lymphoma: too many adverse effects.
    Prescrire Int; 2004 Jun; 13(71):94-7. PubMed ID: 15233146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significant impact of cutaneous T-cell lymphoma on patients' quality of life: results of a 2005 National Cutaneous Lymphoma Foundation Survey.
    Demierre MF; Gan S; Jones J; Miller DR
    Cancer; 2006 Nov; 107(10):2504-11. PubMed ID: 17048251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topical and oral bexarotene.
    Schadt CR
    Dermatol Ther; 2013; 26(5):400-3. PubMed ID: 24099070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Extracorporeal photopheresis in dermatology].
    Pérez-Carmona L; Harto-Castaño A; Díez-Recio E; Jaén-Olasolo P
    Actas Dermosifiliogr; 2009; 100(6):459-71. PubMed ID: 19709550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of a new, single, integrated, closed photopheresis system in patients with cutaneous T-cell lymphoma.
    Bisaccia E; Vonderheid EC; Geskin L
    Br J Dermatol; 2009 Jul; 161(1):167-9. PubMed ID: 19298276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution of clinical and molecular responses to bexarotene treatment in cutaneous T-cell lymphoma.
    Ballanger F; Nguyen JM; Khammari A; Dréno B
    Dermatology; 2010; 220(4):370-5. PubMed ID: 20484880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose oral bexarotene in combination with low-dose interferon alfa in the treatment of cutaneous T-cell lymphoma: clinical synergism and possible immunologic mechanisms.
    McGinnis KS; Junkins-Hopkins JM; Crawford G; Shapiro M; Rook AH; Vittorio CC
    J Am Acad Dermatol; 2004 Mar; 50(3):375-9. PubMed ID: 14988678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maintenance therapy in cutaneous T-cell lymphoma: who, when, what?
    Dummer R; Assaf C; Bagot M; Gniadecki R; Hauschild A; Knobler R; Ranki A; Stadler R; Whittaker S
    Eur J Cancer; 2007 Nov; 43(16):2321-9. PubMed ID: 17707638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psoralen plus long-wave UV-A (PUVA) and bexarotene therapy: An effective and synergistic combined adjunct to therapy for patients with advanced cutaneous T-cell lymphoma.
    McGinnis KS; Shapiro M; Vittorio CC; Rook AH; Junkins-Hopkins JM
    Arch Dermatol; 2003 Jun; 139(6):771-5. PubMed ID: 12810509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring the decrease of circulating malignant T cells in cutaneous T-cell lymphoma during photopheresis and interferon therapy.
    Ferenczi K; Yawalkar N; Jones D; Kupper TS
    Arch Dermatol; 2003 Jul; 139(7):909-13. PubMed ID: 12873887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of cutaneous T-cell lymphoma: an update.
    Young JW
    J Am Osteopath Assoc; 1993 May; 93(5):591-8, 603. PubMed ID: 8314721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small-scale extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma: a report of 3 cases.
    Schreiner T; Gaczkowski A; Scharffetter-Kochanek K; Borberg H
    Transfus Apher Sci; 2005 Apr; 32(2):197-203. PubMed ID: 15784454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma.
    Kannangara AP; Levitan D; Fleischer AB
    J Dermatolog Treat; 2009; 20(3):169-76. PubMed ID: 19016373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel multimodality biologic response modifier therapy, including bexarotene and long-wave ultraviolet A for a patient with refractory stage IVa cutaneous T-cell lymphoma.
    Shapiro M; Rook AH; Lehrer MS; Junkins-Hopkins JM; French LE; Vittorio CC
    J Am Acad Dermatol; 2002 Dec; 47(6):956-61. PubMed ID: 12451388
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.